Xbrane Biopharma Expands In-House Biosimilar Development Capabilities With New Biotech Lab And Invites Participants To Virtual Capital Markets Day On May 17

Xbrane, a late-stage clinical biopharma company today announced the further expansion of its in-house development capabilities by moving into a new and larger lab in over 2000 m2 of facilities at the new Campus Solna outside Stockholm, Sweden. The company’s pipeline consists of a wide range of development candidates originated from Xbrane’s patented high-yield platform technology. This platform positions Xbrane as the most cost-effective biosimilar developer and amongst the top tier global developers.

Capital Markets Day
Xbrane will host a virtual capital markets day for investors, analysts and journalists on May 17, 2021 14:00-15:30 CET. Xbrane will elaborate on its strategy going forward and the next steps in the company's ambition to become a leading global biosimilar developer. The program will also include a virtual show of the recently established development lab.
A detailed program will be announced at the beginning of May.

New biosimilar development lab
The company has established a new biosimilar development lab at Campus Solna outside Stockholm. This lab enables development of production processes for both mammalian cell- and E. coli-based biosimilars, as well as the advanced bio-chemical analytics required for developing biosimilars. Xbrane, together with other leading Swedish Life Science companies and organizations, will form a large cluster in the new Campus Solna focusing on development and innovation in the Life Science sector. Campus Solna is part of the multibillion “Hagastaden” re-development project, north of Stockholm, which includes the new Karolinska Hospital, Karolinska Institute, new apartments and offices. Over 4,000 people will research, work and study on the new Campus Solna (Footnote: Hagastaden – Stockholm växer (vaxer.stockholm) . Campus Solna | Akademiska Hus).

About Xbrane Biopharma
Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis biosimilar candidate, addresses the SEK 106 billions ophthalmic VEGFa inhibitor market. Xlucane is in phase III and filing of marketing authorization application is planned for Q3 2021. Xbrane has additionally three biosimilars in its pipeline targeting SEK 100 billions in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.